Aim: The aim of this study was to present the preliminary psychometric properties of the Psychosocial Assessment Tool 2.0_General (PAT2.0_GEN), a brief screener for psychosocial risk in families of children with inflammatory bowel disease (IBD).
Methods: Caregivers of 42 youth with IBD were recruited and administered a battery of measures including the PAT2.0_GEN and well-validated measures of child emotional and behavioral functioning at baseline and at a 6-month follow-up.
Results: Internal consistency for the PAT2.0_GEN total score was good (α = 0.82). Baseline was significantly associated with the 6-month follow-up (r = 0.79, P < 0.001). Significant correlations between the baseline PAT2.0 _GEN total score and caregiver-reported Child Behavior Checklist total scores at baseline (r = 0.74, P < 0.001) and at a 6-month follow-up (r = 0.62, P < 0.001) support the content and predictive validity of the PAT2.0_GEN. Baseline PAT2.0_GEN was also significantly correlated with youth-reported Child Behavior Checklist total scores at baseline (r = 0.37, P = 0.02) but not at the 6-month follow-up (r = 0.23, P = 0.17).
Conclusions: A number of indicators support the concurrent and predictive utility of the PAT2.0_GEN. The PAT2.0_GEN is a promising tool for screening psychosocial risk that could facilitate the provision of psychosocial services to those patients most in need.
*Center for Treatment Adherence and Self-Management
†Division of Behavioral Medicine and Clinical Psychology
‡Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH.
Address correspondence and reprint requests to Ahna L.H. Pai, PhD, Cincinnati Children's Hospital Medical Center, Division of Behavioral Medicine and Clinical Psychology, Center for Treatment Adherence and Self-Management, 3333 Burnet Ave, MLC 7039, Cincinnati, OH 45229 (e-mail: firstname.lastname@example.org).
Received 13 December, 2012
Accepted 9 August, 2013
This research is supported in part by K23 DK079037; PHS Grant P30 DK 078392; Procter & Gamble Pharmaceuticals; USPHS Grant #UL1 RR026314 from the National Center for Research Resources, National Institutes of Health.
The authors report no conflicts of interest.